Su1492: STRONG HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE ADDITIONAL DOSE AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Kappelman, Michael D.; Weaver, Kimberly N.; Zhang, Xian; Chun, Kelly; Watkins, Runa; Adler, Jeremy; Dubinsky, Marla; Kastl, Art; Bousvaros, Athos; Cross, Raymond; Higgins, Peter; Ungaro, Ryan C.; Bewtra, Meenakshi; Strople, Jennifer A.; Bellaguarda, Emanuelle; Farraye, Francis A.; Dai, Xiangfeng; Boccieri, Margie E; Firestine, Ann; Fernando, Manory; Bastidas, Monique; Zikry, Michael; Long, Millie D.

doi:10.1016/s0016-5085(22)61414-8

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding response of IBD patients to COVID-19 vaccines, a wider breadth of evidence is available, particularly regarding initial response of patients immunized with two doses of the presently available mRNA vaccines (54)(55)(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66)(67)(68)(69)(70). Generally, data collected in IBD patients exposed to COVID-19 vaccines resemble those evidenced after SARS-CoV-2 infection.…”

Section: Immune Response Of Patients With Inflammatory Bowel Disease ...mentioning

confidence: 99%

“…In a study enrolling 1,909 IBD adult patients, differences among vaccines were highlighted (58). It was shown that, within 90 days of the second vaccine dose, patients given mRNA vaccines had antibodies against RBD S protein in 96% of the cases, compared to 81% of those receiving the adenovirus vectored vaccine.…”

Section: Immune Response Of Patients With Inflammatory Bowel Disease ...mentioning

confidence: 99%

See 1 more Smart Citation

Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence

Esposito

Caminiti

Giordano³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD), including Crohn’s disease, ulcerative colitis, and unclassified inflammatory bowel disease, are a group of chronic, immune mediated conditions that are presumed to occur in genetically susceptible individuals because of a dysregulated intestinal immune response to environmental factors. IBD patients can be considered subjects with an aberrant immune response that makes them at increased risk of infections, particularly those due to opportunistic pathogens. In many cases this risk is significantly increased by the therapy they receive. Aim of this narrative review is to describe the impact of SARS-CoV-2 infection and the immunogenicity of COVID-19 vaccines in patients with IBD. Available data indicate that patients with IBD do not have an increased susceptibility to infection with SARS-CoV-2 and that, if infected, in the majority of the cases they must not modify the therapy in place because this does not negatively affect the COVID-19 course. Only corticosteroids should be reduced or suspended due to the risk of causing severe forms. Furthermore, COVID-19 seems to modify the course of IBD mainly due to the impact on intestinal disease of the psychological factors deriving from the measures implemented to deal with the pandemic. The data relating to the immune response induced by SARS-CoV-2 or by COVID-19 vaccines can be considered much less definitive. It seems certain that the immune response to disease and vaccines is not substantially different from that seen in healthy subjects, with the exception of patients treated with anti-tumor necrosis factor alone or in combination with other immunosuppressants who showed a reduced immune response. How much, however, this problem reduces induced protection is not known. Moreover, the impact of SARS-CoV-2 variants on IBD course and immune response to SARS-CoV-2 infection and COVID-19 vaccines has not been studied and deserves attention. Further studies capable of facing and solving unanswered questions are needed in order to adequately protect IBD patients from the risks associated with SARS-CoV-2 infection.

show abstract

Section: Immune Response Of Patients With Inflammatory Bowel Disease ...mentioning

confidence: 99%

Section: Immune Response Of Patients With Inflammatory Bowel Disease ...mentioning

confidence: 99%

Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence

Esposito

Caminiti

Giordano³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Su1492: STRONG HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE ADDITIONAL DOSE AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Cited by 1 publication

References 0 publications

Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence

Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence

Contact Info

Product

Resources

About